Paul Stoffels


Paul Stoffels,

Executive Vice President, Chief Scientific Officer

Dr. Paul Stoffels is Chief Scientific Officer, Johnson & Johnson. In this role, he works with R&D leaders across Johnson & Johnson to set the enterprise-wide innovation agenda, and is a member of the Johnson & Johnson Executive Committee.

Paul chairs the Johnson & Johnson R&D Management Committee and provides oversight to the Johnson & Johnson Development Corporation (JJDC) and Johnson & Johnson Innovation Centers, with the goal of catalyzing innovative science and technology. Additionally, he oversees product safety of all products of the Johnson & Johnson Family of Companies worldwide.

Paul is also Worldwide Chairman, Pharmaceuticals, Johnson & Johnson, with responsibility for expansion of the company’s therapeutic pipeline through global R&D and strategic partnerships, licensing and acquisitions. He oversees teams across the Janssen Pharmaceutical Companies of Johnson & Johnson, which discover and develop treatments for unmet medical needs in the therapeutic areas of cardiovascular & metabolism, immunology, infectious disease & vaccines, neuroscience and oncology.

Prior to his role as Worldwide Chairman, Paul served as Global Head, Johnson & Johnson Pharmaceutical R&D from 2009 - 2011, as Company Group Chairman, Central Nervous System & Internal Medicine, from 2006 - 2009, and as Company Group Chairman, Global Virology, from 2005-2006. Paul joined Johnson & Johnson in 2002 with the acquisition of Virco and Tibotec, where he was Chief Executive Officer of Virco and Chairman of Tibotec, and led the development of a number of leading products for the treatment of HIV.


Neomed (Montreal)
7171 Frederick-Banting
Montreal, Quebec, CANADA H4S 1Z9
(514) 367 1212
Your web browser is out of date. For the most optimal experience, please upgrade to the newest version of IE. Thank You.